0102030405
CAS No 1535212-07-7 Voxilaprevir Pharmaceutical Intermediates
02
Product detail
Product detail
Voxilaprevir is an advanced antiviral compound that plays a crucial role in the treatment of hepatitis C virus (HCV) infections. As a member of the class of drugs known as NS3/4A protease inhibitors, Voxilaprevir works by inhibiting the viral protease enzyme, which is essential for the replication of the virus. This mechanism of action makes it a vital component in combination therapies for HCV, providing patients with a more effective treatment option.
02
product detail
|
Product name |
Voxilaprevir |
|
CAS No. |
1535212-07-7 |
|
EINECS |
/ |
|
Formula |
C40H52F4N6O9S |
|
Molecular Weight |
868.93 |
|
Appearance |
White to off white solid |
|
Purity |
≥98% |
|
Type |
Pharmaceutical Intermediates |
Voxilaprevir is characterized by its unique physical and chemical properties, which contribute to its effectiveness and stability:
- Molecular Formula: C40H52F4N6O9S
- Molecular Weight: 868.93 g/mol
- Appearance: White to off white solid
- Solubility: Soluble in organic solvents such as DMSO and methanol, with limited solubility in water, which is advantageous for formulation in various pharmaceutical preparations.
- Stability: Exhibits high thermal and chemical stability, allowing for extended shelf life and reliable performance in various formulations.
These properties not only enhance the drug's efficacy but also ensure that it can be stored and transported without significant degradation, making it a reliable choice for pharmaceutical manufacturers.
The advantages of Voxilaprevir extend beyond its chemical properties. Here are some key benefits that make it an essential product in the pharmaceutical industry:
1. Efficacy Against Multiple Genotypes: Voxilaprevir has demonstrated effectiveness against various HCV genotypes, making it a versatile option for healthcare providers. This broad-spectrum activity allows for tailored treatment plans that can address the specific needs of patients.
2. Combination Therapy Potential: When used in combination with other antiviral agents, Voxilaprevir enhances the overall efficacy of HCV treatment regimens. This synergistic effect can lead to higher cure rates and improved patient outcomes.
3. Reduced Treatment Duration: Clinical studies have shown that treatment regimens incorporating Voxilaprevir can lead to shorter treatment durations without compromising efficacy. This is particularly beneficial for patients seeking quicker recovery times.
4. Safety Profile: Voxilaprevir has been well-tolerated in clinical trials, with a safety profile that supports its use in diverse patient populations. This aspect is crucial for healthcare providers when considering treatment options.
5. Regulatory Compliance: Our manufacturing processes adhere to the highest international standards, ensuring that Voxilaprevir is produced in compliance with Good Manufacturing Practices (GMP). This commitment to quality guarantees that our product is safe and effective for use in the pharmaceutical industry.
Voxilaprevir represents a significant advancement in the treatment of hepatitis C virus infections. With its robust physical and chemical properties, combined with its efficacy and safety profile, it stands out as a leading choice for pharmaceutical manufacturers and healthcare providers alike. As a production and trade integrated factory, we are dedicated to delivering high-quality products that meet the evolving needs of the pharmaceutical industry. Trust Voxilaprevir for your antiviral needs and experience the difference in patient care and treatment outcomes.
For more information or to place an order, please contact us today!